Selective AKT3 Inhibitor Compounds for Lower-Side-Effect Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments targeting the PI3K/AKT/mTOR pathway, such as PI3K inhibitors and mTOR inhibitors, often cause side effects and negative feedback mechanisms, highlighting the need for effective and selective AKT inhibitors to avoid these issues.
Innovation Solution
Development of a series of compounds represented by specific formulas (I-XII) and their pharmaceutically acceptable salts, which selectively inhibit AKT protein kinase, particularly AKT3, with potential applications in treating cancers like breast, prostate, and ovarian cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If upstream PI3K is inhibited, then cancer cell proliferation is suppressed, but serious side effects occur
Solution Approach 1:
The patent extracts and targets the specific AKT kinase enzyme in the PI3K/AKT/mTOR pathway, rather than inhibiting the entire upstream pathway. By designing compounds that selectively bind to and inhibit AKT (as shown in the chemical structures and IC50 data), the treatment achieves cancer cell suppression while avoiding the broad side effects associated with upstream PI3K inhibition.
Solution Approach 2:
The invention applies local quality by creating highly selective AKT inhibitors with specific molecular structures (as depicted in the chemical formulas) that target only the AKT enzyme's active site. This localized targeting ensures that only the specific pathological pathway is inhibited, leaving other cellular functions intact and avoiding systemic side effects.
2Reliability
If downstream mTOR is inhibited, then cancer progression is blocked, but negative feedback mechanisms reduce drug efficacy
Solution Approach 1:
The patent employs preliminary action by inhibiting AKT upstream of mTOR in the signaling pathway. By blocking AKT activity first (as demonstrated by the compounds' selective AKT inhibition), the downstream mTOR activation that would normally create negative feedback and lead to drug resistance is prevented before it can occur, thereby maintaining sustained therapeutic efficacy.
3Object-affected harmful factors
If AKT inhibitors are developed to improve selectivity, then side effects are reduced, but achieving high potency becomes more difficult
Solution Approach 1:
The invention applies parameter changes by systematically modifying the chemical parameters of the inhibitor molecules (as shown in the various chemical structures with different substituents) to optimize both selectivity and potency. By adjusting molecular weight, hydrophobicity, and specific functional group positioning, the compounds achieve high AKT selectivity while maintaining potent inhibition (IC50 < 10 μM).
Data Source
AI summary
An AKT inhibitor is provided, which specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a preparation method thereof, and the use thereof in prevention and/or treatment of a disease mediated by AKT protein kinase.